Melanotan II
Nonselective melanocortin analog; High cosmetic-risk profile
Brief Overview: Melanotan II is a melanocortin agonist best known for tanning and sexual arousal effects. Because it is nonselective, it can affect pigmentation, appetite, nausea pathways, sexual function, and cardiovascular/autonomic symptoms. Evidence lens: The clinical and regulatory problem is that tanning use is not an approved therapeutic use, and gray-market products create identity, dose, sterility, and contamination risks. Mole and skin-pigment changes are not trivial cosmetic side effects. How to read this: if you're new, avoid treating “sunless tanning” as low risk. Once you're past the basics, focus on MC receptor nonselectivity, dermatology monitoring, melanoma-risk uncertainty, and the distinction between MT-II and FDA-approved bremelanotide/PT-141.
- Melanotan II is a synthetic cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone (alpha-MSH).
- It is an unapproved melanocortin agonist; Unregulated tanning use is not an approved medical use.
- Melanotan II is a cyclic melanocortin agonist with broader receptor activity than Melanotan I/afamelanotide. It is higher-risk and non-approved, not a cosmetic equivalent.
- MT-II acts on melanocortin receptors, including MC1R in melanocytes and CNS melanocortin receptors.
- This explains both tanning effects and systemic adverse effects such as nausea, flushing, appetite change, libido effects, yawning, and blood-pressure or cardiovascular symptoms.
- Its melanocortin activity affects pigmentation, appetite, sexual function, nausea, and autonomic symptoms. The same broad receptor activity that users seek can create adverse effects. The mechanism here is a plausibility map, not proof of a clinical outcome.
- Early human studies showed tanning and sexual-function effects, but the compound was not developed into an approved tanning product.
- Safety concerns include mole darkening, dysplastic nevi, melanoma-case reports, rhabdomyolysis/renal events in case reports, and unpredictable gray-market product quality.
- Human cosmetic/tanning efficacy is not the same as safety validation. Reports and case literature around priapism, nevus changes, and adverse reactions temper community enthusiasm. These are separate tiers of evidence: preclinical data, regional human reports, approved-product evidence, and community anecdotes.
Below you'll find reported clinical-label, research, and community-use dosing contexts where available. It's educational reference only, not dosing instructions for you.
- Protocol 1: Clinical/Trial Protocols - Loading [Clinical/Human Trial]; Route: Subcutaneous (SC); Dose: Loading Dose: 0.025 mg/kg daily; Duration: 2 weeks (Loading); Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
- Protocol 2: Clinical/Trial Protocols - Libido/ED [Clinical/Human Trial]; Route: Subcutaneous (SC); Dose: Libido/ED: 0.025 mg/kg (single dose); Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
- Protocol 3: Common Biohacker Protocols - Loading [Community/Biohacker/Anecdotal]; Route: Subcutaneous (SC); Dose: 0.25 mg – 0.5 mg daily; Duration: Until desired shade is reached; Titration/loading: Many community users start as low as 50-100 mcg (0.1 mg) to assess tolerance before moving to 250 mcg.; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
- Protocol 4: Common Biohacker Protocols - Maintenance [Community/Biohacker/Anecdotal]; Route: Subcutaneous (SC); Dose: 0.5 mg – 1 mg (1–2× per week); Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
- Protocol 5: Common Biohacker Protocols - Libido/ED [Community/Biohacker/Anecdotal]; Route: Subcutaneous (SC); Dose: 0.5 mg – 1 mg (PRN / as needed); Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
- Protocol 6: Community Nasal Spray note [Community/Biohacker/Anecdotal]; Route: Nasal spray; Dose: 1 mg - 2 mg to achieve similar effects to a 0.25 mg injection; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
- Community titration is common but not medically standardized. Nasal spray exposure is especially variable and is not safer than injection by default. Protocol rows are educational context, not personalized instructions, and product-label directions control when an approved product exists.
- Time until steady state: not calculable.
- Half-life basis: Published human PK is not consistent enough for a reliable common-use estimate. Pigmentation and mole changes can outlast measurable exposure; Monitoring skin changes matters more than plasma steady state.
- Beginner translation: this is a deliberately conservative read. A missing steady-state number does not mean the compound has no effect; It means the available human PK data are not strong enough to justify a precise accumulation estimate for common use patterns.
- Practical interpretation: Published pharmacokinetic details vary by route and formulation. Downstream pigmentation effects can outlast measurable exposure.
- Public PK for unapproved products is limited, and route variability is high. Pigmentation can persist beyond active exposure, making dose-response interpretation difficult. PK estimates are most useful for timing and accumulation awareness, not for proving efficacy or safety.
- UV exposure combined with MT-II increases dermatologic effects.
- Do not combine with tanning beds or deliberate high-UV exposure.
- Avoid stacking with PDE5 inhibitors or other pro-erectile agents without strong caution because priapism risk is plausible. UV exposure is a risk amplifier. A sound stack accounts for both mechanism overlap and additive safety, tolerability, and interpretation risks.
- Known risks include nausea, flushing, appetite suppression, spontaneous erections, fatigue, yawning, mole darkening, dysplastic nevi, melanoma concern, blood-pressure effects, priapism risk, kidney injury/rhabdomyolysis case reports, and product-contamination risk.
- Avoid in personal/family melanoma history, dysplastic nevus syndrome, Fitzpatrick I-II skin with heavy mole burden, cardiovascular disease, kidney disease, pregnancy, or concurrent PDE5-inhibitor use unless reviewed by a clinician.
- Major concerns include nausea, flushing, blood pressure effects, spontaneous erections/priapism, mole darkening, melanoma diagnostic confusion, and product impurity. The honest safety picture covers both known risks and uncertainty risks, especially where human data are limited.
- Dermatologic mole checks, blood pressure, renal function if systemic symptoms occur, and urgent evaluation for priapism or severe cardiovascular symptoms.
- Track skin lesions with photos, blood pressure symptoms, nausea, sexual side effects, and sun/UV exposure. Changing moles or prolonged erections are urgent red flags. Useful monitoring matches the claimed goal, the most plausible risk, and objective baseline measures.
- FDA: not approved.
- Australia/TGA: melanotan products are unapproved therapeutic goods and cannot be lawfully supplied without appropriate authorization.
- UK/EU: not authorized.
- WADA: high-risk under S0 for athletes as a non-approved substance.
- Melanotan II is not FDA-approved and is included in safety/compounding concern discussions. Online tanning-product availability does not equal legal or clinical acceptance. Regulatory status spans distinct categories: FDA approval, ex-U.S. approval, investigational development, compounding review, supplement/cosmetic status, and RUO-market availability.